Late DLEK failure patients benefit from repeat endothelial keratoplasty

Article

Repeat endothelial keratoplasty (EK) is effective in improving corneal clarity in patients with failed deep lamellar endothelial keratoplasty (DLEK).

Repeat endothelial keratoplasty (EK) is effective in improving corneal clarity in patients with failed deep lamellar endothelial keratoplasty (DLEK), declares a study published in Cornea.

Dr Peter Kim et al., Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Canada, compiled a retrospective, interventional case series on 10 eyes of 9 patients. Clinical records were reviewed of all participants who experienced failed DLEK surgery and underwent repeat EK surgery. Of the patients included in the study, 7 eyes had their failed DSEK donor disc removed and 3 eyes underwent repeat EK without the removal of the failed donor disc.

All eyes saw vast improvements in corneal clarity and visual acuity. There were no significant postoperative complications recorded after EK surgery.

It was concluded that repeat EK is a suitable and effective alternative to penetrating keratoplasty (PK). Surgery can be performed with or without removing the failed donor disc.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.